BioSpace News Archive

that is, the tumors don’t contain many immune cells, or they have cells that suppress the ability of the immune system to fight them.

Sonoma Pharmaceuticals, Inc. announced that it has commenced a process to explore and evaluate strategic alternatives for its U.S.

Among CStone’s 15 cancer drug candidates, five candidates are in pivotal late-stage clinical development, with a total of 13 on-going registrational trials.

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of its underwritten public offering of 8,000,000 shares of its common stock by certain selling shareholders at a public offering price of $26.50 per share, before underwriting discounts and commissions.

Amazon is donating $1 million to Washington STEM – to support their work in making STEM more accessible, equitable, and meaningful for every Washington student, especially those furthest from opportunity – and $1 million to Pacific Science Center – to develop a new computer science curriculum and expand outreach to 200,000 students in low-income communities

The Chief Public Health Officer and Deputy Chief Public Health Officer will hold a media availability to provide information on a novel coronavirus.

Hoverink Biotechnologies announced today that CEO Debbie Mae Carter will step down and will be succeeded by Cyrus Sajna as CEO and CFO of the company.

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2019 financial results will be reported after the market closes on Monday, March 9.

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that Antonio Gualberto, M.D., Ph.D., will step down as Head of Development and Chief Medical Officer to pursue other opportunities.

Amazentis announces the debut of Timeline, a next generation nutrition product designed to promote healthy aging, as part of the Swiss Food & Nutrition Valley in the House of Switzerland at the World Economic Forum in Davos, Switzerland